Multicenter Randomized Controlled Trial of Vitamin K Antagonist Replacement by Rivaroxaban with or without Vitamin K2 in Hemodialysis Patients with Atrial Fibrillation: the Valkyrie Study.
- 2019-11-08
- RCT · n = 132
- Journal of the American Society of Nephrology : JASN 31(1)
- An S De Vriese
- Rogier Caluwé
- Lotte Pyfferoen
- Dirk De Bacquer
- Koen De Boeck
- Joost Delanote
- Didier De Surgeloose
- Piet Van Hoenacker
- Bruno Van Vlem
- Francis Verbeke
- PubMed: 31704740
- DOI: 10.1681/asn.2019060579
- High evidence
- Large Human Trial
- Highly Cited
- Clinical
Changes in coronary artery, thoracic aorta, and cardiac valve calcium scores and pulse wave velocity were not significantly different among the treatment arms.
- Effect
- Neutral
- Effect size
- Small
- Significant
- No
- Dose
- 2000 µg thrice weekly